Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
To subscribe, please call BIOWORLD Customer Service at (800) 888-3912; outside the U.S. and Canada, call (404) 262-5547.
 

Summary: To subscribe, please call BIOWORLD®
Customer Service at (800) 888-3912; outside the U.S. and Canada, call (404) 262-5547.
Copyright © 2010 AHC Media LLC. Reproduction is strictly prohibited. Visit our web site at www.bioworld.com
Genmab Shares Dive Sharply
on Zalutumumab Phase III Miss
By Cormac Sheridan
BioWorld Today Correspondent
Shares in Genmab A/S slid more than 20 percent Mon-
day on news that zalutumumab, an antibody-targeting epi-
dermal growth factor receptor (EGFR), failed to reach the
primary endpoint of a pivotal Phase III trial in head and
neck cancer.
The Copenhagen, Denmark-based company reported
that patients who received the drug plus best supportive
care attained a median survival of 6.7 months, while those
on best supportive care alone attained a median overall
survival of 5.2 months. However, the result was not statis-
tically significant (p = 0.0648).
The drug did better on a secondary endpoint.
Patients in the drug treatment arm achieved a 61 per-

  

Source: Alon, Uri - Departments of Molecular Cell Biology & Physics of Complex Systems, Weizmann Institute of Science

 

Collections: Biology and Medicine